Tisagenlecleucel (CTL019) is a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. Many leukemias are caused by uncontrolled growth of B cells. B cells have a protein on their surface called CD19. T cells are taken from the patient and treated to make them attack B cells.